Clinical examination of patients with late-onset Pompe disease: typical and not typical symptoms and signs
https://doi.org/10.17650/2222-8721-2019-9-4-26-33
Abstract
Pompe disease is classified in two main forms: the infantile onset Pompe disease, manifested before the age of 12 months and late onset Pompe disease with a debut at any age after 1 year of life. The late onset Pompe disease is characterized by hyper creatine kinase level, limb-girdle and axial muscle weakness, usually complicated by respiratory muscles degeneration. Diagnostic delay is still common in most countries, and physician should be wary to of delaying the correct diagnosis. Difficulties in diagnosing late onset Pompe disease are associated with broad and continuous clinical spectrum of nonspecific signs and symptoms often not distinguishable from those in other neuromuscular disorders. The main muscular manifestations and clinical tests of late onset Pompe disease are considered, and extra-muscular changes are discussed that allow one to suspect type II glycogenosis.
About the Author
S. S. Nikitin
Association of Neuromuscular Disorders Specialists, Medical Center «Practical Neurology»
Russian Federation
Russian Federation
Build. 2, 17 Krzhizhanovskogo St., Moscow 117258
References
1. Mechtler T.P., Stary S., Metz T.F. et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 2012;379(9813):335–41. PMID: 22133539. DOI: 10.1016/S0140-6736(11)61266-X.
2. Dasouki M., Jawdat O., Almadhoun O. et al. Pompe disease: literature review and case series. Neurol Clin 2014;32:751. PMID: 25037089. DOI: 10.1016/j.ncl.2014.04.010.
3. Toscano A., Rodolico C., Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med 2019;7(13):284–95. PMID: 31392196. DOI: 10.21037/atm.2019.07.24.
4. Theadom A., Rodrigues M., Poke G. et al. A nationwide, population-based prevalence study of genetic muscle disorders. Neuroepidemiology 2019; 52(3–4):128–35. PMID: 30661069. DOI: 10.1159/000494115.
5. Nikitin S.S., Kovalchuk M.O., Zaharova E.U., Tsivileva V.V. Late-onset Pompe disease: first clinical description in Russia. Nervno-myshechnye bolezni = Neuromuscular diseases 2014;1:62–8. (In Russ.) DOI: 10.17650/2222-8721-2014-0-1-62-68.
6. van der Beek N. A.M.E., de Vries J.M., Hagemans M.L.C. et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 2012;7:88–103. PMID: 23147228. DOI: 10.1186/1750-1172-7-88.
7. Kishnani P.S., Steiner R.D., Bali D. et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267–88. PMID: 16702877. DOI: 10.1097/01.gim.0000218152.87434.f3.
8. Müller-Felber W., Horvath R., Gempel K. et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term followup in 18 patients. Neuromuscul Disord 2007:17:698–706. PMID: 17643989. DOI: 10.1016/j.nmd.2007.06.002.
9. Güngör D., Schober A.K., Kruijshaar M.E. et al. Pain in adult patients with Pompe disease: a cross-sectional survey. Mol Genet Metab 2013;109:371–6. PMID: 23849261. DOI: 10.1016/j.ymgme.2013.05.021.
10. Gesquière-Dando A., Attarian S., Maues De P.A. et al. Fibromyalgia-like symptoms associated with irritable bowel syndrome: A challenging diagnosis of lateonset Pompe disease. Muscle Nerve 2015;52(2):300–4. PMID: 25703594. DOI: 10.1002/mus.24618.
11. Nikitin S.S., Kurbatov S.A., Bredelev V.A. et al. Alarming signs and symptoms in the early diagnostics of late onset Pompe disease: super omnia clinica. Zhurnal nevrologii i psikhiatrii = Journal of neurology and psychiatry 2015; 12:19–24. (In Russ.) . DOI: 10.17116/jneurol201511511219-24.
12. Pichiecchio A., Uggetti C., Ravaglia S. et al. Muscle MRI in adult-onset acid maltase deficiency. Neuromuscul Disord 2004;14(1):51–5. PMID: 14659413. DOI: 10.1016/j.nmd.2003.08.003.
13. Alejaldre A., Díaz-Manera J., Ravaglia S. et al. Trunk muscle involvement in lateonset Pompe disease: study of thirty patients. Neuromuscul Disord 2012;22(2):S148–54. PMID: 22980766. DOI: 10.1016/j.nmd.2012.05.011.
14. Figueroa-Bonaparte S., Segovia S., Llauger J. et al. Muscle MRI findings in childhood/adult onset Pompe disease correlate with muscle function. PLoS One 2016;11(10):e0163493. PMID: 27711114. DOI: 10.1371/journal.pone.0163493.
15. Taisne N., Desnuelle C., Juntas Morales R. et al. Bent spine syndrome as the initial symptom of late-onset Pompe disease. Muscle Nerve 2017;56(1):167–70. PMID: 27862019. DOI: 10.1002/mus.25478.
16. Gaeta M., Barca E., Ruggeri P. et al. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function. Mol Genet Metab 2013;110:290–6. PMID: 23916420. DOI: 10.1016/j.ymgme.2013.06.023.
17. Spiesshoefer J., Henke C., Kabitz H.J. et al. The nature of respiratory muscle weakness in patients with late-onset Pompe disease. Neuromuscul Disord 2019;29(8):618–27. PMID: 31327549. DOI: 10.1016/j.nmd.2019.06.011.
18. Berger K.I., Chan Y., Rom W.N. et al. Progression from respiratory dysfunction to failure in late-onset Pompe disease. Neuromuscul Disord 2016;26:481–9. PMID: 27297666. DOI: 10.1016/j.nmd.2016.05.018.
19. Johnson E.M., Roberts M., Mozaffar T. et al. Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in lateonset Pompe disease. Neuromuscul Disord 2016;26(2):136–45. PMID: 26794303. DOI: 10.1016/j.nmd.2015.11.009.
20. Dubrovsky A., Corderi J., Lin M. et al. Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation. Muscle Nerve 2011;44(6):897–901. PMID: 21953123. DOI: 10.1002/mus.222027.
21. Carlier R.Y., Laforet P., Wary C. et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. Neuromuscul Disord 2011;21(11):791–9. PMID: 21803581. DOI: 10.1016/j.nmd.2011.06.748.
22. Jones H.N., Crisp K.D., Asrani P. et al. Quantitative assessment of lingual strength in late-onset Pompe disease. Muscle Nerve 2015;51(5):731–5. PMID: 25399907. DOI: 10.1002/mus.24523.
23. Brignol T.N., Urtizberea J.A. Pompe disease and ophthalmopathy: literature review. Nervno-myshechnye bolezni – Neuromuscular Diseases 2015;1:19–24. (In Russ.) . DOI: 10.17650/2222-8721-2015-1-19-24.
24. Groen W.B., Leen W.G., Vos A.M. et al. Ptosis as a feature of late-onset glycogenosis type II. Neurology 2006;67(12):2261–2. PMID: 17190962. DOI: 10.1212/01.wnl.0000249183.39952.3e.
25. Kretzschmar H.A., Wagner H., Hübner G. et al. Aneurysms and vacuolar degeneration of cerebral arteries in lateonset acid maltase deficiency. J Neurol Sci 1990;98(2–3):169–83. PMID: 2243227. DOI: 10.1016/0022-510x(90)90258-o.
26. Refai D., Lev R., Cross D.T. et al. Thrombotic complications of a basilar artery aneurysm in a young adult with Pompe disease. Surg Neurol 2008;70(5):518–20. PMID: 18207222. DOI: 10.1016/j.surneu.2007.05.049.
27. Zhang B., Zhao Y., Liu J. et al. Late-onset Pompe disease with complicated intracranial aneurysm: a Chinese case report. Neuropsychiatr Dis Treat. 2016;12:713–7. PMID: 27099502. DOI: 10.2147/NDT.S94892.
28. Filosto M., Todeschini A., Cotelli M.S. et al. Non-muscle involvement in lateonset glycogenosis II. Acta Myol 2013;32(2):91–4. PMID: 24399865.
29. Laforêt P., Petiot P., Nicolino M. et al. Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology 2008;70(22):2063–6. PMID: 18505979. DOI: 10.1212/01.wnl.0000313367.09469.13.
30. Goeber V., Banz Y., Kaeberich A.et al. Huge aneurysm of the ascending aorta in a patient with adult-type Pompe’s disease: histological findings mimicking fibrillinopathy. Eur J Cardiothorac Surg 2013;43(1):193–5. PMID: 22945242. DOI: 10.1093/ejcts/ezs489.
31. Chan J., Desai A.K., Kazi Z.B. et al. The emerging phenotype of late-onset Pompe disease: A systematic literature review. Mol Genet Metab 2017;120:163–72. DOI: 10.1016/j.ymgme.2016.12.004.
32. Tabarki B., Mahdhaoui A., Yacoub M. et al. Familial hypertrophic cardiomyopathy associated with Wolff– Parkinson–White syndrome revealing type II glycogenosis. Arch Pediatr 2002;9(7):697–700. PMID: 12162158. DOI: 10.1016/s0929-693x(01)00968-x.
33. van der Beek N.A., Soliman O.I., van Capelle C.I. et al. Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities. J Neurol Sci 2008;275(1–2):46–50. PMID: 18757064 DOI: 10.1016/j.jns.2008.07.013.
34. Alandy-Dy J., Wencel M., Hall K. et al. Variable clinical features and genotypephenotype correlations in 18 patients with late-onset Pompe disease. Ann Transl Med 2019;7(13):276. PMID: 31392188 PMID: 31392188. DOI: 10.21037/atm.2019.06.48.
35. Roberts M., Kishnani P.S., van der Ploeg A.T. et al. The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry. Mol Genet Metab 2011;104(4):574–82. PMID: 21930409. DOI: 10.1016/j.ymgme.2011.08.01111.
36. Panosyan F.B., Fitzpatrick M.F., Bolton C.F. Late onset Pompe disease mimicking rigid spine syndrome. Can J Neurol Sci 2014;41(2):286–9. PMID: 24534049. DOI: 10.1017/s0317167100016760.
37. Bernstein D.L., Bialer M.G., Mehta L. et al. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab 2010;101(2–3):130–3. PMID: 20638881. DOI: 10.1016/j.ymgme.2010.06.003.
38. Hanisch F., Rahne T., Plontke S.K. Prevalence of hearing loss in patients with late-onset Pompe disease: Audiological and otological consequences. Int J Audiol 2013;52(12):816–23. PMID: 2416085412. DOI: 10.3109/14992027.2013.840932.
39. McNamara E.R., Austin S., Case L. et al. Expanding our understanding of lower urinary tract symptoms and incontinence in adults with pompe disease. JIMD Rep 2015;20:5–10. PMID: 25614307. DOI: 10.1007/8904_2014_381.
40. Karabul N., Skudlarek A., Berndt J. et al. Urge incontinence and gastrointestinal symptoms in adult patients with Pompe disease: a cross-sectional survey. JIMD Rep 2014;17:53–61. PMID: 25155777. DOI: 10.1007/8904_2014_334.
41. Remiche G., Herbaut A.G., Ronchi D. et al. Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition. Eur Neurol 2012;68(2):75–8. PMID: 22760201. DOI: 10.1159/000338776.
42. Forsha D., Li J.S., Smith P.B. et al. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med 2011;13:625–31. PMID: 21543987. DOI: 10.1097/GIM.0b013e3182142966.
43. Angelini C., Semplicini C., Ravaglia S. et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 2012;259(5):952–8. PMID: 22081099. DOI: 10.1007/s00415-011-6293-5.
44. Mori M., Bailey L.A., Estrada J. et al. Severe Cardiomyopathy as the Isolated Presenting Feature in an Adult with LateOnset Pompe Disease: a case report. JIMD Rep 2017;31:79–83. PMID: 27142047. DOI: 10.1007/8904_2016_563.
45. van der Beek N.A., Verschuure H., Reuser A.J.J. et al. Hearing in adults with Pompe disease. J Inherit Metab Dis 2012;35:335–41. PMID: 22002441. DOI: 10.21037/atm.2019.06.48.
46. Alandy-Dy J., Wencel M., Hall K. et al. Variable clinical features and genotypephenotype correlations in 18 patients with late-onset Pompe disease. Ann Transl Med 2019;7(13):276. PMID: 31392188. DOI: 10.21037/atm.2019.06.48.
47. Musumeci O., Catalano N., Barca E. et al. Auditory system involvement in late onset Pompe disease: a study of 20 Italian patients. Mol Genet Metab 2012;107:480–4. PMID: 22958975. DOI: 10.1016/j.ymgme.2012.07.024.
48. Finsterer J., Wanschitz J., Quasthoff S. et al. Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease. Acta Neurol Scand 2017;136(6):558–69. PMID: 28295152. DOI: 10.1111/ane.12758.
49. Origuchi Y., Itai Y., Matsumoto S. et al. Quantitative histological study of the sural nerve in a child with acid maltase deficiency(glycogenosis type II). Pediatr Neurol 1986;2:346–9.
50. Fidziańska A., Ługowska A., Tylki-Szymańska A. Late form of Pompe disease with glycogen storage in peripheral nerves axons. J Neurol Sci 2011;15: 301(1–2):59–62. PMID: 21109266. DOI: 10.1016/j.jns.2010.10.031.
51. Hobson-Webb L.D., Austin S.L., Jain S. et al. Small-fiber neuropathy in Pompe disease: first reported cases and prospective screening of a clinic cohort. Am J Case Rep 2015;16:196–201. PMID: 25835646. DOI: 10.12659/AJCR.893309.
52. Tsai L.K., Hwu W.L., Lee N.C. et al. Clinical features of Pompe disease with motor neuronopathy. Neuromuscul Disord 2019;9(11):903–6. PMID: 31706699. DOI: 10.1016/j.nmd.2019.09.011.
53. Lamartine S., Monteiro M., Remiche G. Late-onset Pompe disease associated with polyneuropathy. Neuromuscul Disord 2019;29(12):968–72. PMID: 31676142. DOI: 10.1016/j.nmd.2019.08.016.
54. Bernstein D.L., Bialer M.G., Mehta L. et al. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab 2010;101(2–3):130–3. PMID: 20638881. DOI: 10.1016/j.ymgme.2010.06.003.
55. Remiche G., Herbaut A.G., Ronchi D. et al. Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition. Eur Neurol 2012;68(2):75–8. PMID: 22760201. DOI: 10.1159/000338776.
56. Nikitin S.S. Asymptomatic hypercreatinkinazemia in the clinic of neuromuscular diseases. Nevrologicheskiy zhurnal = Neurologic Journal 2015;20(5):26–33. (In Russ.) .
57. Finsterer J., Scorza F.A., Scorza C.A. Significance of Asymptomatic Hyper Creatine-Kinase Emia. J Clin Neuromuscul Dis 2019;41(2):90–102. PMID: 31743252. DOI: 10.1097/CND.0000000000000269.
58. Gutiérrez-Rivas E,. Bautista J., Vílchez J.J. et al. Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: a spanish cohort. Neuromuscul Disord 2015;25(7):548–53. PMID: 25998610. DOI: 10.1016/j.nmd.2015.04.008.
59. Preisler N., Lukacs Z., Vinge L. et al. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. Mol Gen Metab 2013;109:171–3. PMID: 24011652. DOI: 10.1016/j.ymgme.2013.08.005.
60. Savost’yanov K.V., Nikitin S.S., Karpacheva K.E. Laboratory studies and Pompe disease: from suspicion to therapy monitoring. Nervno-myshechnye bolezni = Neuromuscular diseases 2016;6(1):54–62. (In Russ). DOI: 10.17650/2222-8721-2016-6-1-54-62.
61. Winchester B., Bali D., Bodamer O.A. et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 2008;93(3):275–81. PMID: 18078773. DOI: 10.1016/j.ymgme.2007.09.006.
62. Lindberg C., Anderson B., Engvall M. et al. Search for Pompe disease among patients with undetermined myopathies. Acta Neurol Scand 2016;133(2):131–5. PMID: 26190396. DOI: 10.1111/ane.12460.
Review
For citations:
Nikitin S.S. Clinical examination of patients with late-onset Pompe disease: typical and not typical symptoms and signs. Neuromuscular Diseases. 2019;9(4):26-33. (In Russ.) https://doi.org/10.17650/2222-8721-2019-9-4-26-33
Views:
1535
Email this article 